| 1/9 | US=89 / Biol/Mol Hao H, Zhou HS, McMasters KM. Chemosensitization of tumor cells: inactivation of nuclear factor-kappa B associated with chemosensitivity in melanoma cells after combination treatment with E2F-1 and doxorubicin. In: Walther W, Stein US. Gene therapy of cancer: methods and protocols. 2ª ed. New Jersey: Humana Press, 2009. p. 301-13. (Methods in Molecular Biology, 542) ISBN 978-1-59745-561-9. CANCER; QUIMIOSSENSIBILIZACAO; CELULAS TUMORAIS; FATOR NUCLEAR-KAPPA; QUIMIOSENSIBILIDADE; MELANOMA; E2F-1; DOXORRUBICINA; APOPTOSE; MOBILIDADE ELETROFORETICA |
| 2/9 | US=103 / Câncer Makwana V, Simmons S, Missailidis S. Aptamers as anticancer agents. In: Missailidis S. Anticancer therapeutics. New Jersey: Wiley Blackwell, 2008. p. 331-45. ISBN 978-0-470-72303-6. AGENTES ANTICANCERIGENOS; APTAMEROS; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; NUCLEOLIN; PROTEINA E2F; FATOR DE CRESCIMENTO DERIVADO DE PLAQUETAS; ANTIGENO PROSTATICO ESPECIFICO DE MEMBRANA |
| 3/9 | US=47 / Câncer Knudsen ES, Braden WA. RB-pathway: cell control and cancer therapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 1-17. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. VIA RB; CONTROLE DO CANCER; TERAPIA CELULAR; SUPRESSOR DE TUMOR; RETINOBLASTOMA; CICLINAS; QUIMIOTERAPIA; TERAPIA DE ALVO MOLECULAR; CICLO CELULAR; E2F; ANTIMETABOLITOS; AGENTES ANTIMICROTUBULOS |
| 4/9 | US=58 / Câncer Pentimalli F, Cito L, Giordano A. Dysfunction of the RB retinoblastoma gene in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 109-22. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DISFUNCAO DO GENE; RETINOBLASTOMA RB NO CANCER; RETINOBLASTOMA; FAMILIA RB; SUPRESSORES TUMORAIS; CICLO CELULAR; G1-S DE TRANSICAO; CHECKPOINTS; E2F |
| 5/9 | US=111 / Câncer Dirlam A, Macleod KF. The retinoblastoma tumour suppressor. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 282-97. ISBN 978-0-470-01852-1. CANCER; SUPRESSOR DE TUMOR; RETINOBLASTOMA; REGULACAO DA ATIVIDADE E2F; FOSFORILACAO; PRB; MORTE CELULAR PROGRAMADA; QUIMIOSENSIBILIDADE; RETINA |
| 6/9 | US=46 / Câncer Brown VD, Gallie BL. Molecular genetics of retinoblastoma. In: Meyers RA. Cancer: from mechanisms to therapeutic approaches. New Jersey: Wiley-Blackwell, 2007. p. 311-37. ISBN 978-3-527-31768-4. GENETICA MOLECULAR DO RETINOBLASTOMA; APOPTOSE; E2F; LOH; PROBAND; RB1; RETINOBLASTOMA; SV40; TAG; SUPRESSOR TUMORAL |
| 7/9 | US=46 / Câncer La Thangue NB. Theoretical foundations of cancer chemotherapy. In: Meyers RA. Cancer: from mechanisms to therapeutic approaches. New Jersey: Wiley-Blackwell, 2007. p. 369-87. ISBN 978-3-527-31768-4. CANCER; QUIMIOTERAPIA; DESENHO DE DROGAS; TERAPIA; P53; CICLO CELULAR; ANGIOGENESE; HSP90; ERB B; E2F |
| 8/9 | US=57-B / Biol/Mol Weinberg RA. pRb and control of the cell cycle clock. In: ___. The biology of cancer. New York: Garland Science, 2007. p. 255-306. ISBN 0-8153-4078-8. PRB; CONTROLO DO RELOGIO DO CICLO CELULAR; CICLINA-CDK; ONCOPROTEINAS VIRAIS; FACTORES DE TRANSCRICAO E2F |
| 9/9 | US=68 / Biol/Mol Dasgupta P, Chellappan SP. Chromatin immunoprecipitation assays. In: Fisher PB. Cancer genomics and proteomics: methods and protocols. New Jersey: Humana Press, 2007. p. 135-52. (Methods in Molecular Biology, 383) ISBN 978-1-58829-504-0. ENSAIOS DE IMUNOPRECIPITACAO DE CROMATINA; ACETILACAO; CHIP; E2F; MODIFICACAO DAS HISTONAS; IMUNOPRECIPITACAO; MICROARRAYS |